ArticleJournal of neurotrauma2016
Bone Marrow Stromal Cell Intraspinal Transplants Fail to Improve Motor Outcomes in a Severe Model of Spinal Cord Injury.
Article in Journal of neurotrauma, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Combined PLGA scaffolds and therapeutic stem cells for locomotion recovery in spinal cord-injured rats: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Advances and Challenges in Spinal Cord Injury Treatments.Journal of clinical medicine · 2024Review
- Current insights into the management of spinal cord injury.Journal of orthopaedics · 2023Article
- Challenges in Translating Regenerative Therapies for Spinal Cord Injury.Topics in spinal cord injury rehabilitation · 2023Article
- Multimodal Repair of Spinal Cord Injury With Mesenchymal Stem Cells.Neurospine · 2022Article
- Mesenchymal Stromal Cell Therapy in Spinal Cord Injury: Mechanisms and Prospects.Frontiers in cellular neuroscience · 2022Review
- Cell transplantation to repair the injured spinal cord.International review of neurobiology · 2022Article
- Thermosensitive quaternized chitosan hydrogel scaffolds promote neural differentiation in bone marrow mesenchymal stem cells and functional recovery in a rat spinal cord injury model.Cell and tissue research · 2021Article
- Exosomes derived from miR-26a-modified MSCs promote axonal regeneration via the PTEN/AKT/mTOR pathway following spinal cord injury.Stem cell research & therapy · 2021Article
- Reversion of Injured Adult Neurons to an Embryonic State by Grafts of Neural Progenitor Cells After Spinal Cord Injury.Neuroscience bulletin · 2021Article
- A nerve growth factor persistent delivery scaffold seeded with neurally differentiated bone marrow mesenchymal stem cells promoted the functional recovery of spinal cord injury in rats.American journal of translational research · 2021Article
- Novel innovations in cell and gene therapies for spinal cord injury.F1000Research · 2020Review
- Hypoxic preconditioned bone mesenchymal stem cells ameliorate spinal cord injury in rats via improved survival and migration.International journal of molecular medicine · 2018Article
- Lycopsamine Exerts Protective Effects and Improves Functional Outcome After Spinal Cord Injury in Rats by Suppressing Cell Death.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Multichannel polymer scaffold seeded with activated Schwann cells and bone mesenchymal stem cells improves axonal regeneration and functional recovery after rat spinal cord injury.Acta pharmacologica Sinica · 2017Article
- Biomaterial-Supported Cell Transplantation Treatments for Spinal Cord Injury: Challenges and Perspectives.Frontiers in cellular neuroscience · 2017Review
- Mesenchymal stem cells overexpressing XIST induce macrophage M2 polarization and improve neural stem cell homeostatic microenvironment, alleviating spinal cord injury.Journal of tissue engineeringArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone marrow stromal cells (BMSCs) have been reported to exert potential neuroprotective properties in models of neurotrauma, although precise mechanisms underlying their benefits are poorly understood. Despite this lack of knowledge, several clinical trials have been initiated using these cells. To determine whether local mechanisms mediate BMSC neuroprotective actions, we grafted allogeneic BMSCs to sites of severe, compressive spinal cord injury (SCI) in Sprague-Dawley rats. Cells were administered 48 h after the original injury. Additional animals received allogeneic MSCs that were genetically modified to secrete brain-derived neurotrophic factor (BDNF) to further determine whether a locally administered neurotrophic factor provides or extends neuroprotection. When assessed 2 months post-injury in a clinically relevant model of severe SCI, BMSC grafts with or without BDNF secretion failed to improve motor outcomes. Thus, allogeneic grafts of BMSCs do not appear to act through local mechanisms, and future clinical trials that acutely deliver BMSCs to actual sites of injury within days are unlikely to be beneficial. Additional studies should address whether systemic administration of BMSCs alter outcomes from neurotrauma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.